Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joyce A Goldstein

Showing results (21-30 of 55) with videos related to

Pageof 6
Sort By:
Molecular Pharmacology|May 17, 2014
Regulation of human CYP2C9 expression by electrophilic stress involves activator protein 1 activation and DNA loopingNgome L Makia, Sailesh Surapureddi, Katalin Monostory, et al.
Molecular Pharmacology|June 23, 2012
Human CYP2C8 is post-transcriptionally regulated by microRNAs 103 and 107 in human liverShu-Yun Zhang, Sailesh Surapureddi, Sherry Coulter, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 7, 2005
Recombinant CYP3A4*17 is defective in metabolizing the hypertensive drug nifedipine, and the CYP3A4*17 allele may occur on the same chromosome as CYP3A5*3, representing a new putative defective CYP3A haplotypeSu-Jun Lee, Douglas A Bell, Sherry J Coulter, et al.
Pharmacotherapy|June 25, 2003
Losartan and E3174 pharmacokinetics in cytochrome P450 2C9*1/*1, *1/*2, and *1/*3 individualsCraig R Lee, John A Pieper, Alan L Hinderliter, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|January 21, 2010
Hepatocyte nuclear factor 4{alpha} regulates rifampicin-mediated induction of CYP2C genes in primary cultures of human hepatocytesRitu Rana, Yuping Chen, Stephen S Ferguson, et al.
Clinical Pharmacology and Therapeutics|November 12, 2002
Evaluation of cytochrome P4502C9 metabolic activity with tolbutamide in CYP2C91 heterozygotesCraig R Lee, John A Pieper, Alan L Hinderliter, et al.
The Journal of Pharmacology and Experimental Therapeutics|August 16, 2005
Functional characterization of novel allelic variants of CYP2C9 recently discovered in southeast AsiansTracy C DeLozier, Soo-Chin Lee, Sherry J Coulter, et al.
Pharmacogenetics|April 3, 2002
Analysis of the CYP2C19 polymorphism in a North-eastern Thai populationWichittra Tassaneeyakul, Arporn Tawalee, Wongwiwat Tassaneeyakul, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|October 13, 2006
A new CYP3A5 variant, CYP3A5*11, is shown to be defective in nifedipine metabolism in a recombinant cDNA expression systemSu-Jun Lee, Ilse P van der Heiden, Joyce A Goldstein, et al.
Pharmacogenetics and Genomics|April 27, 2007
The discovery of new coding alleles of human CYP26A1 that are potentially defective in the metabolism of all-trans retinoic acid and their assessment in a recombinant cDNA expression systemSu-Jun Lee, Lalith Perera, Sherry J Coulter, et al.
Pageof 6

Showing results (21-30 of 55) with videos related to

Sort By:
Pageof 6
Molecular Pharmacology|May 17, 2014
Regulation of human CYP2C9 expression by electrophilic stress involves activator protein 1 activation and DNA loopingNgome L Makia, Sailesh Surapureddi, Katalin Monostory, et al.
Molecular Pharmacology|June 23, 2012
Human CYP2C8 is post-transcriptionally regulated by microRNAs 103 and 107 in human liverShu-Yun Zhang, Sailesh Surapureddi, Sherry Coulter, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 7, 2005
Recombinant CYP3A4*17 is defective in metabolizing the hypertensive drug nifedipine, and the CYP3A4*17 allele may occur on the same chromosome as CYP3A5*3, representing a new putative defective CYP3A haplotypeSu-Jun Lee, Douglas A Bell, Sherry J Coulter, et al.
Pharmacotherapy|June 25, 2003
Losartan and E3174 pharmacokinetics in cytochrome P450 2C9*1/*1, *1/*2, and *1/*3 individualsCraig R Lee, John A Pieper, Alan L Hinderliter, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|January 21, 2010
Hepatocyte nuclear factor 4{alpha} regulates rifampicin-mediated induction of CYP2C genes in primary cultures of human hepatocytesRitu Rana, Yuping Chen, Stephen S Ferguson, et al.
Clinical Pharmacology and Therapeutics|November 12, 2002
Evaluation of cytochrome P4502C9 metabolic activity with tolbutamide in CYP2C91 heterozygotesCraig R Lee, John A Pieper, Alan L Hinderliter, et al.
The Journal of Pharmacology and Experimental Therapeutics|August 16, 2005
Functional characterization of novel allelic variants of CYP2C9 recently discovered in southeast AsiansTracy C DeLozier, Soo-Chin Lee, Sherry J Coulter, et al.
Pharmacogenetics|April 3, 2002
Analysis of the CYP2C19 polymorphism in a North-eastern Thai populationWichittra Tassaneeyakul, Arporn Tawalee, Wongwiwat Tassaneeyakul, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|October 13, 2006
A new CYP3A5 variant, CYP3A5*11, is shown to be defective in nifedipine metabolism in a recombinant cDNA expression systemSu-Jun Lee, Ilse P van der Heiden, Joyce A Goldstein, et al.
Pharmacogenetics and Genomics|April 27, 2007
The discovery of new coding alleles of human CYP26A1 that are potentially defective in the metabolism of all-trans retinoic acid and their assessment in a recombinant cDNA expression systemSu-Jun Lee, Lalith Perera, Sherry J Coulter, et al.
Pageof 6